Patient perception of Breezhaler ® and Ellipta ® device feedback mechanisms in COPD: The ADVANTAGE Study.
| Autor: | Altman P; a Global Med Affairs - Respiratory, Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA., Bergna MA; b Respiratory Research, CEMER Centro Médico de Enfermedades Respiratorias , Buenos Aires , Argentina., Garcia GR; c Pneumology, Cenasma Institute , Buenos Aires , Argentina., Guerin T; d Novartis Product Lifecycle Services, Novartis Pharmaceuticals & Novartis Global Services Center , Dublin , Ireland., Pino AV; e Respiratory Franchise, Novartis Argentina SA , Buenos Aires , Argentina., Whiteford JL; d Novartis Product Lifecycle Services, Novartis Pharmaceuticals & Novartis Global Services Center , Dublin , Ireland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current medical research and opinion [Curr Med Res Opin] 2019 Feb; Vol. 35 (2), pp. 221-227. Date of Electronic Publication: 2018 May 15. |
| DOI: | 10.1080/03007995.2018.1464437 |
| Abstrakt: | Objectives: The primary objective of the ADVANTAGE study was to compare device-naïve chronic obstructive pulmonary disease (COPD) patients' perception of the Breezhaler ® and Ellipta ® devices' feedback mechanisms of dose delivery confirmation. The secondary objective was to assess comfort with the inhalers' mouthpiece in terms of ease to form a tight seal around the mouthpiece. These objectives were achieved by using a novel, patient perception of inhaler questionnaire developed and tested during cognitive interviews of patients by Evidera, London, United Kingdom. Methods: Ten COPD patients were interviewed to collect feedback on the interpretation, relevance and language of the questionnaire. This questionnaire was then used in ADVANTAGE to compare patients' perception (n = 100) of both devices. Patients completed the questionnaire after a single inhalation of placebo through each inhaler. Results: Using the final questionnaire, patients reported being more confident of the feedback mechanism of Breezhaler than that of the Ellipta device (mean score 4.3 versus 3.6 respectively, estimated difference [95% CI]: 0.75 [0.51, 0.99], p < .0001). Patients also reported better comfort (ease to form a tight seal with the lips) with the Breezhaler mouthpiece than the Ellipta mouthpiece (mean score 4.3 versus 3.9 respectively, estimated difference [95% CI]: 0.41 [0.21, 0.61], p < .0001). There were no safety concerns associated with either device. Conclusion: COPD patients showed greater preference for the Breezhaler over the Ellipta inhaler for confidence of dose delivery and comfort of the mouthpiece. Trial Registration: The trial is registered at ClinicalTrials.gov (ClinicalTrials.gov number NCT02551224). |
| Databáze: | MEDLINE |
| Externí odkaz: |
|